Literature DB >> 8898159

Lymph node metastases and prognosis in patients with stage IA2 cervical cancer.

S L Buckley1, D M Tritz, L Van Le, R Higgins, B U Sevin, F R Ueland, P D DePriest, H H Gallion, C L Bailey, R J Kryscio, W Fowler, H Averette, J R van Nagell.   

Abstract

Ninety-four patients with squamous cell carcinoma invading the cervical stroma to a depth of >3.0-5.0 mm with 7 mm or less in horizontal spread (FIGO Stage IA2) were evaluated. Depth and lateral extent of stromal invasion were verified using an ocular micrometer. Cell type and lymph vascular space invasion (LVSI) were recorded in each case. Patients were treated primarily by radical hysterectomy with pelvic lymphadenectomy, and those with lymph node metastases were offered postoperative radiation. Following treatment, patients were seen at 3-month intervals for 2 years, and every 6 months thereafter. The mean duration of follow-up was 6.9 years (range 0.4-23.5 years). Seven of 94 patients (7.4%) had lymph node metastases. Five patients had 1 positive node, 1 patient had 2 positive nodes, and 1 patient had 3 positive nodes. Five patients developed recurrent cancer and 4 died of disease. LVSI was present in 31 cases (33%). Tumor recurrence was significantly increased in patients with positive LVSI (9.7% vs 3.2%). The 5-year survival rate of patients with LVSI was 89% vs 98% in patients without this finding (P = 0.058). The 5-year survival rate of all Stage IA2 cervical cancer patients was 95%. Patients with Stage IA2 cervical cancer have a significant risk of lymph node metastases and should be treated by radical hysterectomy with pelvic lymphadenectomy. LVSI is an important prognostic variable in these patients and should be recorded in all cases.

Entities:  

Mesh:

Year:  1996        PMID: 8898159     DOI: 10.1006/gyno.1996.0268

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  4 in total

Review 1.  Fertility preserving options in patients with gynecologic malignancies.

Authors:  Ramez N Eskander; Leslie M Randall; Michael L Berman; Krishnansu S Tewari; Philip J Disaia; Robert E Bristow
Journal:  Am J Obstet Gynecol       Date:  2011-03-16       Impact factor: 8.661

2.  USPIO-enhanced MRI for preoperative staging of gynecological pelvic tumors: preliminary results.

Authors:  Thomas M Keller; Sven C A Michel; Johannes Fröhlich; Daniel Fink; Rosmarie Caduff; Borut Marincek; Rahel A Kubik-Huch
Journal:  Eur Radiol       Date:  2004-02-26       Impact factor: 5.315

3.  Age-Dependent Hematologic Toxicity Profiles and Prognostic Serologic Markers in Postoperative Radiochemotherapy Treatment for Uterine Cervical Cancer.

Authors:  Eva Meixner; Line Hoeltgen; Philipp Hoegen; Laila König; Nathalie Arians; Laura L Michel; Katharina Smetanay; Carlo Fremd; Andreas Schneeweiss; Jürgen Debus; Juliane Hörner-Rieber
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

4.  Robotically assisted endoscopic ovarian transposition.

Authors:  Kelly L Molpus; June S Wedergren; Mark A Carlson
Journal:  JSLS       Date:  2003 Jan-Mar       Impact factor: 2.172

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.